Dr. Farideh Bischoff appointed VP of Clinical Research for Imagion Biosystems

Company dedicated to enhancing healthcare through earlier detection of cancer, Imagion Biosystems, asserted the appointment of Farideh Bischoff, PhD as the Vice President of Clinical Research. Dr. Bischofff will spearhead the clinical program for the company’s Magsense cancer detection technology that aims to achieve regulatory approval as a diagnostic device for the early detection of malignant tumor cells.

Dr Bischoffs brings on board several years of experience in oncology product commercialization.Some of her key achievements include scientific development, regulatory submission and successful commercialization of molecular diagnostics for Biocept. She has led innumerable productive collaborative studies including NIFTY NIH Fetal Cell Study, composed of individuals from academic, pharmaceutical and biotech organisations.

She is known for her finesse and  expertise in the fields of rare cancer detection, molecular cytogenetics, diagnostic assay development and validation. Dr Bischoff holds a PhD from the University of Texas Graduate School of Biological Sciences, Houston. Her doctoral thesis led to the discovery of the p53 tumor suppressor gene and the emergence of a productive new avenue of global cancer research.

Imagion Executive Chairman and CEO Bob Proulx said “We are very pleased to welcome Dr Bischoff to Imagion Biosystems as we progress toward first-in-human clinical studies.”